INTERLEUKIN-2 ACTIVITY OF COLONIC LAMINA PROPRIA MONONUCLEAR-CELLS IN A RAT MODEL OF EXPERIMENTAL COLITIS

被引:22
作者
GURBINDO, C
RUSSO, P
SABBAH, S
LOHOUES, MJ
SEIDMAN, E
机构
[1] HOP ST JUSTINE,CTR RECH,DIV PEDIAT GASTROENTEROL,INTESTINAL IMMUNOL LAB,MONTREAL H3T 1C5,QUEBEC,CANADA
[2] HOP ST JUSTINE,CTR RECH,DEPT PATHOL,MONTREAL H3T 1C5,QUEBEC,CANADA
[3] UNIV MONTREAL,DEPT PEDIAT,MONTREAL H3C 3J7,QUEBEC,CANADA
[4] UNIV MONTREAL,DEPT MED,MONTREAL H3C 3J7,QUEBEC,CANADA
关键词
D O I
10.1016/0016-5085(93)90262-B
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Altered interleukin 2 (IL-2) production has been implicated in the pathogenesis of inflammatory bowel diseases. Methods: The temporal relationship between IL-2, prostaglandin E2 (PGE2) production, and mucosal injury was evaluated by isolated colonic lamina 3 propria mononuclear cells (LPMC), using the trinitrobenzene sulfonic acid model of rat colitis. Results: Spontaneous LPMC IL-2 activity was significantly increased in chronic (5 weeks) but not acute (5 days) or resolved colitis groups. IL-2 activity after concanavalin A activation was highest in the groups with resolved and chronic colitis. PGE2 production was significantly increased in LPMC cultures in acute or chronic colitis as well as the ethanol control groups but not the resolved colitis group. The addition of indomethacin to LPMC cultures decreased PGE2 levels in all groups, whereas IL-2 activity increased only for the chronic and resolved colitis groups. No correlation was found between PGE2 and IL-2 production by LPMC. Conclusions: In this experimental model, LPMC IL-2 production varied according to the severity and duration of the inflammation. Increased PGE2 production does not appear to be responsible for the IL-2 alterations in colitis. © 1993.
引用
收藏
页码:964 / 972
页数:9
相关论文
共 44 条
[1]  
BECK PL, 1988, INFLAMM BOWEL DIS, P201
[2]   INCREASED CONCENTRATIONS OF INTERLEUKIN 1-BETA, INTERLEUKIN-2, AND SOLUBLE INTERLEUKIN-2 RECEPTORS IN ENDOSCOPIC MUCOSAL BIOPSY SPECIMENS WITH ACTIVE INFLAMMATORY BOWEL-DISEASE [J].
BRYNSKOV, J ;
TVEDE, N ;
ANDERSEN, CB ;
VILIEN, M .
GUT, 1992, 33 (01) :55-58
[3]   A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL OF CYCLOSPORINE THERAPY IN ACTIVE CHRONIC CROHNS-DISEASE [J].
BRYNSKOV, J ;
FREUND, L ;
RASMUSSEN, SN ;
LAURITSEN, K ;
DEMUCKADELL, OS ;
WILLIAMS, N ;
MACDONALD, AS ;
TANTON, R ;
MOLINA, F ;
CAMPANINI, MC ;
BIANCHI, P ;
RANZI, T ;
DIPALO, FQ ;
MALCHOWMOLLER, A ;
THOMSEN, OO ;
TAGEJENSEN, U ;
BINDER, V ;
RIIS, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (13) :845-850
[4]  
BRYNSKOV JJ, 1992, GUT, V31, P795
[5]  
DAUPHINEE MJ, 1981, J IMMUNOL, V127, P2483
[6]   T-CELL ABNORMALITIES IN INFLAMMATORY BOWEL-DISEASE ARE MEDIATED BY INTERLEUKIN-2 [J].
EBERT, EC ;
WRIGHT, SH ;
LIPSHUTZ, WH ;
HAUPTMAN, SP .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1984, 33 (02) :232-244
[7]  
FAIS S, 1987, CLIN EXP IMMUNOL, V68, P605
[8]  
FIOCCHI C, 1984, GASTROENTEROLOGY, V86, P734
[9]  
FLESCHER E, 1992, CLIN EXP IMMUNOL, V87, P435
[10]  
GILLIS S, 1978, J IMMUNOL, V120, P2027